$408.88
▲ +0.3% Today
as of Aug 5, 16:45 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 3
● 19
▼ 3
Morgan Stanley Adjusts Price Target on Amgen to $351 From $333, Maintains Equalweight Rating
Amgen (AMGN) Lifted 2026 Guidance, Is The Valuation Still Too Rich?
Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive
Overview
52-week range
$268
$391
100% of range
Avg surprise (last 2)
+16.1%
Avg reaction (last 1)
-2.5%
0% positive
Latest IV / EM
40%
EM ±2.4% · $408 · Aug 7
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $3.34 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $5.93 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $6.02 | $5.26 | +14.4% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $4.90 | $4.16 | +17.8% | — | -2.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $5.22 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $1.38 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.21 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $3.22 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $2.57 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $2.74B | — | $3.08B | $3.01B | $2.97B | — | $3.31B | $3.24B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $2.67B | — | $2.53B | $2.66B | $1.18B | — | $2.05B | $1.91B |
| Net income | $1.82B | — | $3.22B | $1.43B | $1.73B | — | $2.83B | $746M |
| EPS (diluted) | $3.34 | — | $5.93 | $2.65 | $3.20 | — | $5.22 | $1.38 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $12.04B | $9.13B | $9.45B | $8.03B | $8.81B | $11.97B | $9.01B | $9.30B |
| Inventory | $6.19B | $6.22B | $6.35B | $6.58B | $6.73B | $7.00B | $7.36B | $8.00B |
| Total current assets | $31.48B | $29.06B | $27.89B | $26.73B | $26.93B | $29.03B | $26.77B | $27.21B |
| Total assets | $92.50B | $90.59B | $90.14B | $87.90B | $89.37B | $91.84B | $90.88B | $90.91B |
| Long-term debt | $51.89B | $50.01B | $52.43B | $53.76B | $54.01B | $56.55B | $56.85B | $57.12B |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $9.19B | $8.66B | $9.62B | $7.43B | $6.21B | $5.88B | $7.53B | $5.92B |